These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22853875)

  • 1. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
    Hayashi Y; Xiao L; Suzuki A; Blum MA; Sabloff B; Taketa T; Maru DM; Welsh J; Lin SH; Weston B; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Ajani JA
    Eur J Cancer; 2012 Dec; 48(18):3396-404. PubMed ID: 22853875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomograms for predicting overall and recurrence-free survival after trimodality therapy for esophageal adenocarcinoma.
    Merritt RE; Abdel-Rasoul M; Souza DM; Kneuertz PJ
    J Surg Oncol; 2021 Mar; 123(4):881-890. PubMed ID: 33333590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
    Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
    Goense L; van Rossum PSN; Xi M; Maru DM; Carter BW; Meijer GJ; Ho L; van Hillegersberg R; Hofstetter WL; Lin SH
    Ann Surg Oncol; 2018 Jun; 25(6):1598-1607. PubMed ID: 29569125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.
    Vlacich G; Samson PP; Perkins SM; Roach MC; Parikh PJ; Bradley JD; Lockhart AC; Puri V; Meyers BF; Kozower B; Robinson CG
    Cancer Med; 2017 Dec; 6(12):2886-2896. PubMed ID: 29139215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation.
    Miyata H; Yamasaki M; Takiguchi S; Nakajima K; Fujiwara Y; Mori M; Doki Y
    Oncol Rep; 2010 May; 23(5):1331-7. PubMed ID: 20372848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.
    Koshy M; Greenwald BD; Hausner P; Krasna MJ; Horiba N; Battafarano RJ; Burrows W; Suntharalingam M
    Am J Clin Oncol; 2011 Jun; 34(3):259-64. PubMed ID: 20686405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
    Kim GJ; Koshy M; Hanlon AL; Horiba MN; Edelman MJ; Burrows WM; Battafarano RJ; Suntharalingam M
    Am J Clin Oncol; 2016 Apr; 39(2):136-41. PubMed ID: 24487417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.
    Shao MS; Wong AT; Schwartz D; Weiner JP; Schreiber D
    Ann Thorac Surg; 2016 Jun; 101(6):2148-54. PubMed ID: 27016842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.
    Mitchell KG; Ikoma N; Nelson DB; Maru DM; Erasmus JJ; Weston BR; Vaporciyan AA; Antonoff MB; Mehran RJ; Rice DC; Roth JA; Swisher SG; Sepesi B; Walsh GL; Correa AM; Das P; Blum MA; Badgwell BD; Hofstetter WL
    Ann Thorac Surg; 2019 Sep; 108(3):845-851. PubMed ID: 31102632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.
    Taketa T; Correa AM; Suzuki A; Blum MA; Chien P; Lee JH; Welsh J; Lin SH; Maru DM; Erasmus JJ; Bhutani MS; Weston B; Rice DC; Vaporciyan AA; Hofstetter WL; Swisher SG; Ajani JA
    Oncology; 2012; 83(5):300-4. PubMed ID: 22964903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of recurrence after trimodality therapy for esophageal cancer.
    Dorth JA; Pura JA; Palta M; Willett CG; Uronis HE; D'Amico TA; Czito BG
    Cancer; 2014 Jul; 120(14):2099-105. PubMed ID: 24711267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Esophageal cancer: outcome according to therapeutic strategy].
    Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
    Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.